Research programme: psychoplastogen therapeutics - Collaborations Pharmaceuticals
Latest Information Update: 29 Mar 2023
Price :
$50 *
At a glance
- Originator Collaborations Pharmaceuticals
- Class Drug withdrawal therapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Opioid-related disorders
Most Recent Events
- 21 Mar 2023 Research programme: psychoplastogens therapeutics - Collaborations Pharmaceuticals is available for licensing as of 21 Mar 2023. https://www.collaborationspharma.com/pipeline
- 21 Mar 2023 Preclinical trials in Opioid-related disorders in USA (unspecified route), before March 2023 (Collaborations Pharmaceuticals pipeline, March 2023)